~~<i id='E81008C69E'><strike id='E81008C69E'><tt id='E81008C69E'><pre id='E81008C69E'></pre></tt></strike></i>~~

Home» focus» Wikipedia

Wikipedia

author：Wikipedia 2025-10-02 03:30:00 Page View：8689

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： White House drug shortages task force keeps mum with Congress
Next article： Peter Hotez and the public health issue of online harassment

explore

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Abbott's new heart device gets FDA advisory panel nod

ThedeviceiscalledtheTriClip,anditaddressesadiseasecalledtricuspidregurgitation:aheartconditionthatca

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Resistance to opioid

AdobeAtitssurface,itseemslikeasimpleproblemwithasimplesolution.Acrossthecountry,medicinecabinetsarel